Prostate Cell News Volume 14.32 | Aug 25 2023

    By
    Bob
    -
    0
    14








    2023-08-25 | PCN 14.32


    Prostate Cell News by STEMCELL Technologies
    Vol. 14.32 – 25 August, 2023
    TOP STORY

    LncRNA SNHG4 Promotes Prostate Cancer Cell Survival and Resistance to Enzalutamide through a Let-7a/RREB1 Positive Feedback Loop and a ceRNA Network

    Investigators uncovered a novel molecular mechanism of lncRNA SNHG4 in driving prostate cancer progression and enzalutamide resistance.
    [Journal of Experimental & Clinical Cancer Research]

    Full Article
    Activate, expand, and differentiate your cells with cytokines, chemokines, and growth factors from STEMCELL Technologies.
    PUBLICATIONSRanked by the impact factor of the journal

    P300/SP1 Complex Mediating Elevated METTL1 Regulates CDK14 mRNA Stability via Internal m7G Modification in CRPC

    The authors found that methyltransferase 1 (METTL1) was elevated in CRPC and that patients with METTL1 elevation tended to have a poor prognosis.
    [Journal of Experimental & Clinical Cancer Research]

    Full Article

    Targeting SphK1/2 by SKI-178 Inhibits Prostate Cancer Cell Growth

    Ectopic overexpression of sphingosine kinase 1 (SphK1) and SphK2, by lentiviral constructs, promoted primary prostate cancer cell proliferation and migration.
    [Cell Death & Disease]

    Full Article

    Triggering Pyroptosis Enhances the Antitumor Efficacy of PARP Inhibitors in Prostate Cancer

    Researchers demonstrated that GSDME activity was robustly induced in olaparib-treated cells undergoing pyroptosis, and that high methylation of the GSDME promoter dampened its activity in prostate cancer cells.
    [Cellular Oncology]

    Abstract

    Protein Kinase D Activity Is a Risk Biomarker in Prostate Cancer That Drives Cell Invasion by a Snail/ERK Dependent Mechanism

    The authors investigated protein kinase D function on prostate cancer cell motility, analyzing the underlying molecular mechanisms.
    [Biochimica Et Biophysica Acta-Molecular Basis Of Disease]

    Full ArticleGraphical Abstract

    Generating a Murine PTEN Null Cell Line to Discover the Key Role of p110β-PAK1 in Castration-Resistant Prostate Cancer Invasion

    In vitro, scientists found that androgen deprivation significantly enhanced prostate cancer cell migration/invasion via the p110β isoform-depended PAK1-MAPK activation.
    [Molecular Cancer Research]

    Abstract

    Evodiamine Impairs HIF1A Histone Lactylation to Inhibit Sema3A-Mediated Angiogenesis and PD-L1 by Inducing Ferroptosis in Prostate Cancer

    Evodiamine markedly blocked lactate-induced angiogenesis by restricting histone lactylation and expression of HIF1A in prostate cancer cells.
    [European Journal of Pharmacology]

    Abstract

    Dankasterone a Induces Prostate Cancer Cell Death by Inducing Oxidative Stress

    MTT results showed dankasterone A was cytotoxic to prostate cancer cells, with an IC50 of 5.10 μM for PC-3 cells and 3.41 μM for 22Rv1 cells.
    [European Journal of Pharmacology]

    Abstract

    Dynamic Interplay between Sortilin and Syndecan-1 Contributes to Prostate Cancer Progression

    Scientists showed that there was a dynamic balance between sortilin and syndecan-1, that reported on different metabolic phenotypes.
    [Scientific Reports]

    Full Article
    Watch a webinar on using patient-derived iPS cells to model diabetes.
    REVIEWS

    Chimeric Antigen Receptor-Modified T Cells Therapy in Prostate Cancer: A Comprehensive Review on the Current State and Prospects

    The authors elucidate different types of prostate tumor-associated antigen targets, such as prostate-specific membrane antigen and prostate stem cell antigen and their effects.
    [Heliyon]

    Full ArticleGraphical Abstract
    INDUSTRY AND POLICY NEWS

    Exelixis and Ipsen Announce Positive Results from Phase III CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

    Exelixis, Inc. and Ipsen announced that the global phase III CONTACT-02 pivotal trial met one of two primary endpoints, demonstrating a statistically significant improvement in progression-free survival at the primary analysis.
    [Ipsen]

    Press Release

    LYNPARZA® (olaparib)Plus Abiraterone and Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

    AstraZeneca and Merck announced that LYNPARZA in combination with abiraterone and prednisolone has been approved in Japan to treat adult patients with BRCA-mutated mCRPC.
    [Merck]

    Press Release
    FEATURED EVENT

    BioCon Asia 2023 – Advanced Cell & Gene Therapy (ACGT) Conference

    October 12 – 13, 2023
    Singapore & Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Research Fellow – Prostate Cancer

    Cedars-Sinai – Los Angeles, California, United States

    Research Fellow – Genito-Urinary Cancers

    University of South Australia – Adelaide, Australia

    Postdoctoral Associate – Prostate Cancer Metastasis

    Stony Brook University – Stony Brook, New York, United States

    Postdoctoral Fellow – Prostate Cancer Research

    Georgia Cancer Center at Augusta University – Augusta, Georgia, United States

    Research Associate – Recombinant Protein

    Creative Biolabs – New York, New York, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter